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Background: Beta-blockade is contraindicated in severe aortic regurgitation (AR) due to the fear of prolonging
diastole and thus aggravate regurgitation. However, this has never been scientifically proven and positive effects of
targeting the sympathetic system in AR has been demonstrated in several studies.
Method: Thirty-nine Sprague–Dawley rats with AR were randomized to ten weeks of medical treatment with
carvedilol or no treatment. Treatment was initiated either early or late after AR induction. The effect of carvedilol
was assessed by serial echocardiography and invasive hemodynamic measurements.
Results: AR resulted in eccentric hypertrophy and left ventricular (LV) dysfunction. LV remodeling and function as
measured by echocardiography was unaffected by treatment. LV dimensions were similar between treated and
untreated groups and measures of LV performance (including strain and strain rate) were also unaltered. This result
was confirmed by invasive measurements showing maximal and minimal pressure–time development, LV volumes,
and LV pressures, to be unaltered by treatment. On the contrary, despite relative bradycardia carvedilol did not
reflect any negative impact on the heart.
Conclusion: Carvedilol did not improve left ventricular remodeling or function in rats with surgically induced AR.
Despite relative bradycardia, we did not find carvedilol to negatively impact the heart, either when treatment was
initiated early or late in the course of disease.
Keywords: Aortic regurgitation; Heart valvular disease; Experimental animal studies; Echocardiography; Invasive
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Chronic aortic regurgitation (AR) is a common heart
valve disease with high morbidity and mortality rates
once symptoms occur (Dujardin et al. 1999). However,
disease–progression is often gradual and patients with
even severe degree of regurgitation may be asymptom-
atic for decades without any need of surgical interven-
tion (Bonow et al. 1991; Goldbarg and Halperin 2008).
Ultimately, left ventricular (LV) compensatory mecha-
nisms are exhausted, which results in LV dilation and
dysfunction and consequently heart failure and eventually* Correspondence: tabraha3@jhmi.edu
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in any medium, provided the original work is pdeath (Maurer 2006). The time of surgical intervention
(aortic valve replacement/repair (AVR)) relies on when pa-
tients develop symptoms or when significant alterations in
LV size or function occurs (Bonow et al. 2008; Vahanian
et al. 2012). Medical treatment of AR has been debated for
decades and results from clinical studies have been equivo-
cal (Levine and Gaasch 1996; Evangelista et al. 2005; Lin
and Stewart 2011). Thus, medical management of AR is
not routinely recommended.
Long–term cardiac overload, as seen in congestive
heart failure, leads to over–activation of the sympathetic
and renin–angiotensin–aldosterone system (Schrier and
Abraham 1999). This results in various deleterious ef-
fects (Levine et al. 1982; Bristow 1984) and reversal of
this state has demonstrated beneficial effects on thean Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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line treatment in congestive heart failure (Hunt et al.
2009; McMurray et al. 2012). The use of beta-blockers
in AR is however controversial, mostly due to the risk of
prolonging diastole, which could aggravate regurgitation.
Only a few studies have addressed the effects of beta–
blockade in volume overload, but the rationale for tar-
geting the sympathetic system in AR has been shown by
Champetier et al. (Champetier et al. 2009). They found
several pathophysiological similarities between hearts
from rats with AR and hearts exposed to other types of
cardiac disease. Furthermore, in a study by Plante et al.
(Plante et al. 2004) it was shown that treating AR for
24 weeks with metoprolol had a global impact on the
heart, resulting in improved LV function and reduction
in LV remodeling. Additionally, it has been shown in ex-
perimental and clinical studies that beta-blockers reduce
mortality in chronic AR (Plante et al. 2008; Sampat et al.
2009). However, experimental studies testing the effects
of beta–blockade in AR have only tested the effects of
treatment started early in the course of disease. In a
clinical setting, patients may have AR for years before
the condition is discovered, and at this time–point LV
changes may be too advanced to exploit the positive ef-
fects of beta–blockade. Thus starting treatment late may
induce an increase in regurgitation–volume that could
disturb the balance between load and compensatory
mechanisms.
We therefore undertook this study to investigate the
effects of beta-blockade in a setting reproducing a clin-
ical situation where treatment is initiated at different
time points along the course of disease.
Results
Clinical data
Five rats died during the study–period; one from the AR
(early) group, two from the AR + CAR (early) group, one
from the AR (late) group, and one from the AR + CAR
(late) group. All rats dying were found dead in the
morning with no preceding signs of heart failure. At sac-
rifice heart weight in sham (early) operated rats wasTable 1 Morphometric data at sacrifice
EARLY
Sham AR AR + CAR Disease p-value
(n = 8) (n = 7) (n = 7)
Rat Weight 717 ± 20 666 ± 15 698 ± 17 0,12
Heart weight (g) 1.66 ± 0.07 2.32 ± 0.12 2.32 ± 0.17 0.003*
LV weight (g) 1.17 ± 0.05 1.69 ± 0.10 1.73 ± 0.13 0.002*
RV weight (g) 0.26 ± 0.01 0.36 ± 0.02 0.32 ± 0.02 0.005*
Lung weight (g) 1.59 ± 0.03 2.00 ± 0.25 2.04 ± 0.35 0,45
Weights at sacrifice in sham, treated (Carvedilol), and untreated (AR) rats. Disease p
p–value indicate difference between treated and untreated groups. Left ventricle (Lsignificantly lower than in rats with AR (early), while
no significant difference was found between AR and
AR +CAR in either the early or the late treated groups,
Table 1. Furthermore we did not find any differences in
lung tissue weights among groups.
Echocardiographic data
At baseline no echocardiographic differences were ob-
served between groups. Rats with AR developed eccen-
tric hypertrophy with increased LV dimensions (LVEDD
and LVESD) and wall thickness, Table 2. Additionally,
AR resulted in LV dysfunction. Carvedilol had no effect
on this, and echocardiographic measures of LV remodel-
ling was unaffected by treatment in both the early and
late treated group, Figure 1. Also the rate of LV systolic
dysfunction–development measured by conventional or
speckle-tracking echocardiography was unaltered by
treatment in both groups, Figure 2.
Thus, we did not find carvedilol to alter the development
of eccentric remodeling or LV dysfunction as measured by
echocardiography, regardless of treatment–start.
Hemodynamic measurements
Invasive hemodynamic measurements were performed
at baseline and repeated immediately before sacrifice. Al-
though only borderline significant in the late treated
group we observed a lower heart rate in carvedilol–
treated compared to untreated rats.
Carvedilol did not result in any significant improve-
ment in LV maximum or minimum pressure–time de-
velopment (dp/dtmax and dp/dtmin) or LV volumes
(relative end diastolic or end systolic volume) compared
to untreated rats. Furthermore, end–diastolic and end–
systolic LV pressures were unaltered by treatment in
both study-legs, Table 3. We found tau to be lower in
treated compared to untreated rats in the late treated
group, while other measures of LV diastolic function
was unchanged by treatment. It may reflect less ECM
disturbance in the treated group, but this is an isolated
finding and should be interpreted in the scope of a low
sample size.LATE
Treatment p-value AR AR + CAR Treatment p-value
(n = 5) (n = 7)
0,75 739 ± 54 715 ± 11 0,85
1,00 2.27 ± 0.25 2.28 ± 0.15 0,98
0,95 1.65 ± 0.17 1.72 ± 0.11 0,75
0,46 0.34 ± 0.05 0.32 ± 0.02 0,70
0,99 1.72 ± 0.11 1.65 ± 0.05 0,60
-values indicate difference between sham and untreated groups. Treatment
V), right ventricle (RV). *p < 0.05.
Table 2 Echocardiographic data
EARLY LATE




AR AR + CAR Treatment
p-value
(n = 8) (n = 7) (n = 7) (n = 5) (n = 7)
LVIDd (mm) 9.1 ± 0.24 11.3 ± 0.37 11.1 ± 0.50 0.001* 0,92 10.9 ± 0.50 11.0 ± 0.36 0,92
LVIDs (mm) 5.4 ± 0.23 7.7 ± 0.39 7.6 ± 0.57 0.001* 0,99 6.9 ± 0.46 6.7 ± 0.50 0,88
Wall thickness (mm) 2.0 ± 0.03 2.2 ± 0.07 2.2 ± 0.06 0.019* 0,87 2.4 ± 0.07 2.3 ± 0.08 0,45
FS (%) 41.4 ± 1.50 31.9 ± 1.53 31.70 ± 2.47 0.001* 1,00 37.3 ± 0.02 38.7 ± 0.03 0,75
Strain (%) −22.15 ± 1.23 −18.5 ± 1.12 −18.5 ± 0.98 0,075 1,00 −17.0 ± 0.38 −18.1 ± 1.16 0,49
Echocardiographic data after twelve (left) and twenty-two (right) weeks of severe AR. Disease p-values indicate difference between sham and untreated (AR)
groups. Treatment p-value indicates difference between treated (Carvedilol) and untreated (AR). All p-values are from paired analysis. Left ventricle end-diastolic
diameter (LVEDD), left ventricle end-systolic diameter (LVESD), fractional shortening (FS), and wall thickness (WT). *p < 0.05.
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or significantly change LV hemodynamic conditions,
either when treatment was started early or late in the
course of disease.
Discussion
In this study of rats with surgically induced AR we dem-
onstrate the cardiac effects of carvedilol when treatment
is initiated early and late in the course of disease. Rats
with AR clearly developed eccentric remodeling. Treat-
ment with carvedilol did not change this. Thus, we found
LV–function and remodeling, as measured by echocardi-
ography and invasive hemodynamic catheterization to be
unaltered by ten weeks of carvedilol treatment. Carvedilol
induced relative bradycardia without revealing negative
impact on the heart.
In a clinical setting AVR is indicated in patients with
chronic severe AR once symptoms or significant alter-
ations in LV size or function occurs (Vahanian et al.
2007; Bonow et al. 2008). AVR is an effective treatment
with good long-term prognosis if performed at the cor-
rect time (Klodas et al. 1997). However, open chest sur-
gery and anticoagulant treatment carries a considerable
peri–operative risk. Consequently, medical therapy to
alleviate LV load and ultimately postpone the time of
surgery has long been sought (Lin and Stewart 2011).
Blockade of the sympathetic system
In heart failure it is known that activation of neurohor-
monal systems exerts deleterious effects on the heart
(Bristow 1984). Additionally, when chronically increased,
high concentrations of circulating catecholamines are
cardiotoxic and the extra inotropic and chronotropic
drive results in excessive oxygen expenditure (Mann
et al. 1992). Blocking this over–activation can reverse
these negative effects. Nevertheless, due to the risk of
bradycardia and the following increase in regurgitation
and afterload, beta-blockers are contraindicated in se-
vere AR. This relies on little scientific proof and the timeis right to investigate this further. Recently it was shown
that sustained volume overload activate neurohormonal
systems, similar to other types of cardiac disease, and
genetic studies has proven beta–blockade to reverse up–
regulated genes related to this over–activation (Suzuki
et al. 1997; Champetier et al. 2009; Zendaoui et al.
2011). In our study the aim of treatment was to only
bluntly inhibit the sympathetic system, as to reduce the
risk of negative consequences on the heart while still
exploiting the possible positive biological properties of
carvedilol. This was achieved by a small dose of carve-
dilol to only mildly reduced HR. In previous studies of
AR a similar small dose of beta-blockers has been used,
but has mainly investigating the effects of early-started
treatment (Suzuki et al. 1997; Plante et al. 2004; Zendaoui
et al. 2011). Treatment was well tolerated in both (early
and late started) groups and we did not observe any reflec-
tions of negative consequences on hemodynamic and
morphometric measurements, as would be expected
if regurgitation was significantly increased (e.g. cardiac
incompensation).
LV remodeling and function
Severe AR is initially characterized by a long compen-
sated phase, where hemodynamic consequences of sus-
tained volume overload causes an adaptive increase in
LV volumes without reduction in LV performance. Ec-
centric hypertrophy develops to compensate the initial
overload–burden, but once compensatory mechanisms
are exhausted, more ventricular load results in further
remodeling and increased afterload. In this process, loss of
elastin and alterations in collagen fiber organization results
in decreased LV compliance and increased stiffness. Grad-
ually filling pressures and cardiac work increases that ul-
timately result in decreased cardiac performance.
Similar to the natural history in man, we observed AR
rats to develop LV remodeling. This process started early
after AR-induction and continued throughout the course
of disease. This confirms the findings of Plante et al.
Figure 1 LV dimensions. LV dimensions measured by serial echocardiography in sham-operated (sham), treated (Carvedilol), and untreated (AR)
in the early (left) and late (right) treated groups.
Eskesen et al. SpringerPlus  (2015) 4:52 Page 4 of 9(Champetier et al. 2009) who found in a model of ex-
perimental AR that sarcomeric alpha–actin and smooth
muscle alpha–actin protein were significantly increased
along with increased levels of mRNA for several ECM
component, including collagen I and III. This was
reflected on LV dilation and increased relative wall
thickness measured by echocardiography. In their study
early started metoprolol reduced LV end systolic diam-
eter but did not change wall thickness. This was ex-
plained by a change in several ECM components ratherthan reversal of myocyte proteins. Similarly, in a study
by Zendaoui et al. (Zendaoui et al. 2011), a high–dose
beta–blocker initiated early has shown comparable ef-
fects. Thus, they found six months of treatment to re-
duce end–systolic diameter and expression of mRNA for
collagen I, while echocardiographic measures of hyper-
trophy was unaffected. We found a similar result of un-
changed hypertrophy in both early and late treated
groups, although we found no difference in LV diameters.
This could be explained by differences in AR severity and
Figure 2 LV function. LV function measured by different echocardiographic techniques in sham-operated (sham), treated (Carvedilol), and
untreated (AR) in the early (left) and late (right) treated groups. Strain rate (SR).
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long-term versus short-term treatment regimes. As an iso-
lated result we found (tau) to be decreased in the late
treated group, which could reflect less ECM disturbance.
In conclusion these results indicate that beta–blockade
may positively influence LV dimensions but has not shown
to be able to consistently reduce myocyte hypertrophy.We did not find any difference in positive or negative
dp/dt and LV filling pressures were similar between sham–
operated and rats with AR in both study–legs. Treatment
did not affect this. These results partly confirm the finding
of others.
Previous studies have shown inconsistent effects on LV
performance. In one study, long–term treatment with
Table 3 Invasive hemodynamics
Panel a Early
Sham AR AR + CAR p-value
(n = 6) (n = 6) (n = 5)
HR 355 ± 11 324 ± 7 305 ± 20 0.04*
ESP (mmHg) 120 ± 7.73 124 ± 9.45 136 ± 8.28 0,75
EDP (mmHg) 6.3 ± 1.7 4.9 ± 1.3 8.2 ± 2.1 0,87
ESV (arbitrary units) 18.8 ± 0.85 23.1 ± 1.14 20.8 ± 0.99 0,55
EDV (arbitrary units) 21.2 ± 0.89 26.1 ± 1.56 22.8 ± 1.1 0,39
Tau (msec) 12.5 ± 0.90 11.5 ± 0.88 13.8 ± 1.12 0,67
dp/dt maximum (mmHg/sec) 7419 ± 292 7284 ± 303 7831 ± 333 0,81
dp/dt minimum (mmHg/sec) −7139 ± 314 −5317 ± 376 −6351.6 ± 765 0,42
Panel b LATE
AR AR + CAR p-value
(n = 4) (n = 7)
HR 368 ± 14 333 ± 12 0.09
ESP (mmHg) 148 ± 4.1 149 ± 10.0 0,35
EDP (mmHg) 7.2 ± 0.50 12.6 ± 0.57 0,16
ESV (arbitrary units) 21.3 ± 0.85 20.7 ± 0.47 0,26
EDV (arbitrary units) 23.7 ± 0.78 22.6 ± 1.37 0,86
Tau (msec) 18.2 ± 1.47 13.2 ± 0.99 0.03*
dp/dt maximum (mmHg/sec) 6473 ± 386 7770 ± 443 0,52
dp/dt minimum (mmHg/sec) −7120 ± 1473 −6635 ± 594 0,54
SBP (mmHg) 131 ± 5.6 146 ± 7.7 0,36
DBP (mmHg) 65.0 ± 3.3 70.3 ± 5.5 0,26
Invasive hemodynamic measurements at sacrifice in the early (panel a) and late treated (panel b) groups. P-values are from paired analysis comparing treated
(Carvedilol) and untreated (AR) groups. Pressure-volume time development (dp/dt), end-systolic pressure (ESP), end-diastolic pressure (EDP), end-systolic volume
(ESV), end-diastolic volume (EDV), systolic blood pressure (SBP), and diastolic blood pressure (DBP). *p < 0.05.
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LVEF after 6 and 12 months (Plante et al. 2008), while
another study showed dp/dtmin to be significantly in-
creased by disease and dp/dtmax to be unaffected, while
high–dose carvedilol did not change this. In the same
study LVEF measured by echocardiography decreased
marginally in rats with AR (LVEF 77 ± 0.8% in sham vs.
66 ± 0.5% in AR) and carvedilol slightly reversed this
mild decrease (71 ± 1.4% in treated vs. 66 ± 0.5% in un-
treated rats). In another study invasive hemodynamic
measurements were not performed but echocardiog-
raphy showed improved systolic and diastolic function
in rats treated early with metoprolol for twenty–four
weeks. However, in this study LV systolic function was
also only marginally affected by treatment. We did not
find carvedilol to improve LV systolic function. In the
studies showing positive effects systolic function, LVEF
was within the limits of reference and did not decrease
significantly during the course of disease. This may re-
flect a more benign type of AR where six months of se-
vere volume overload does not impair systolic function.Our model somehow resulted in a reduction in LV
function measured by FS and speckle tracking echocar-
diography and may represent a more progressive type of
disease less susceptible to the positive effects of beta–
blockade.
Although we were unable to show carvedilol to im-
prove LV remodeling and performance, regardless of
treatment start, we did not find beta–blokade to nega-
tively impact the heart.
Limitations
For several reasons (e.g. great biological differences) ani-
mal studies cannot and should never be extrapolated to
humans.
Using a higher dose of carvedilol or a different beta-
blocker (e.g. a selective) may show more pronounced re-
sults. However, we sought to only bluntly inhibit the
sympathetic system in fear of increasing regurgitation.
The dose of carvedilol chosen resulted in a heart rate
drop of 5-10% compared to non-treated AR groups. This
is similar to what has previously shown significant
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though selective and non-selective beta-blockers have
pharmacological actions in common they differ greatly,
and cannot be directly compared. Thus, we interpret our
results in the scope hereof.
Due to a small sample size it is hard to conclude defini-
tively on our results and thus we suggest a larger scale
study to investigated this interesting field. However, we be-
lieve that we have interpreted our findings accordingly.
Conclusion
Carvedilol did not improve left ventricular remodeling
or performance in rats with surgically induced severe
AR. Despite relative bradycardia, we did not find carve-
dilol to negatively impact the heart, either when treat-
ment was initiated early or late in the course of disease.
Methods
Animal model
AR was created in rats by echocardiography–guided
closed–chest operation, as described elsewhere (Arsenault
et al. 2002). Briefly, two aortic valve leaflets were punctured
in a retrograde manner by a right–sided carotid arteriot-
omy. Isoflurane (1.5-2.0% mixed with oxygen) sedation
was followed by an intra peritoneal cocktail (ketamine
90 mg kg−1 and Xylazine 10 mg kg−1) injection. AR perfor-
ation and severity was confirmed by echocardiography dur-
ing the procedure. Treatment was performed by mixing
carvedilol (10 mg/kg/d) in transgenic dough–diet (Bioserv:
Frenchtown, NJ, U.S.A.), which was fed to rats daily for
the duration of medical treatment. All animal experi-
ments were approved by the Johns Hopkins University
Institutional Animal Care and Use Committee.
Early treatment protocol
The twenty-five male Sprague Dawley rats (age 19–20
weeks: Charles River: Wilmington, MA, U.S.A.) included
in this part of the study were divided into three groups:
Sham–operated rats receiving no treatment (Sham
(early), n = 8), rats with AR receiving no medical treat-
ment (AR (early), n = 8), and rats treated with carvedilol
beginning two weeks after AR induction (AR + CAR
(early), n = 9). In sham–operated rats all procedures
were performed, except perforation of aortic valves. All
rats were sacrificed twelve weeks after induction of AR.
Late treatment protocol
Fourteen male Sprague Dawley rats (age 9–10 weeks)
were subjected to severe AR and divided into two
groups: Controls with severe AR receiving no medical
treatment (AR (late), n = 6) and rats with severe AR
treated with carvedilol beginning at twelve weeks after
induction of AR (AR + CAR (late), n = 8). All rats were
sacrificed twenty–two weeks after induction of AR.Echocardiography
Echocardiography was performed on a Vivid 7 machine
(GE Healthcare: Horton, Norway) with a 14 MHZ linear
vascular probe in unconscious rats anesthetized with gas
(Isoflurane 1.5–2.0%). Examinations were performed at
following time points: Early study: 0 (baseline), 2, 6, 9
and 12 weeks after AR induction. Late study: 0 (base-
line), 2, 6, 9, 10, 12, 16, 19, 22 weeks after AR induction.
Regurgitation was confirmed by a color-Doppler ratio of
regurgitant jet >50% of the LV outflow tract diameter.
LV measurements were assessed by conventional M-mode
echocardiography; end diastolic diameter (LVEDD), end
systolic diameter (LVESD), shortening fraction (FS) and
wall thickness (WT). Measurements were averaged from
four beats, two parasternal long–axis (PLAX) and two
short–axis (SAX) planes. FS was calculated as [LVEDD–
LVESD]/ [LVEDD]. As a measure of WT, septum and LV
posterior wall were averaged. Speckle tracking was per-
formed by acquiring 2D cine loops from at least six
cardiac cycles, in mid–ventricular SAX plane at frame
rates >70 s−1. Tracking was performed by using at least
three consecutive cardiac cycles in EchoPAC’s strain mo-
dality analysis software (v. 7.0, GE Healthcare, Waukesha,
WI, U.S.A.). Averaged circumferential deformation repre-
sented by the global trace was used. For strain–rate mea-
surements the global traces were used.
Hemodynamic measurements
A micro–tip conductance pressure–volume catheter (Millar
Instruments, Inc.: Houston, TX, U.S.A.) was inserted into
the heart by right–sided carotid arteriotomy using a classic
closed–chest approach (Pacher et al. 2008). Pressure-
volume (PV) loops were obtained under resting conditions.
Measurements were performed at baseline and immediately
before sacrifice.
Statistical analysis
By comparing sham and untreated rats the overload
caused by AR was documented. The effect of medical
treatment was documented by comparing untreated AR-
rats with carvedilol-treated AR-rats. The difference be-
tween multiple groups was analyzed with ANOVA and
Tukey’s test for multiple comparisons. Serial measure-
ments were compared by repeated measures. All p–values
are two–tailed and a significance level of 0.05 was used.
Statistics are given as mean ± SEM, unless stated otherwise.
All analysis were performed using SAS® software (SAS for
windows, release 9.1, SAS Institute Inc., Cary, NC, U.S.A.)
and PASW statistics 18.0 (SPSS IBM for Macintosh, release
18.0.3, Armonk, USA).
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